Stock Spotlight: ResMed Inc. (ASX:RMD)
This week's Stock Spotlight is ASX-listed ResMed Inc.
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Source: Yahoo Finance
Key Stats
Key Stats
Source: Yahoo Finance. Data as of 07/08/25.
Price Performance

Growth Potential
- Global leader in a significantly under-penetrated sleep apnea market. High barriers to entry in establishing global distribution channels.
- Strong R&D program ensuring RMD remains ahead of competitors.
- New product launches (momentum in new mask releases) & buildout of portfolio via bolt-on acquisitions is seeing RMD become the one-stop shop for sleep apnear.
- Increasing popularity of GLP-1s is increasing awareness with studies indicating patients with an OSA diagnosis and prescribed a GLP-1 drug are 11% more likely to initiate PAP therapy.
- Strong balance sheet and attractive free cash flow profile provides management significant strategic flexibility.
- Solid FY26 guidance with further upside to gross margin.
- Capital management – active share buyback (shares to be repurchased expected at $150m per quarter for FY26).
Key Risks
- Disruptive technology leads to better patient compliance or introduction of alternative therapies (GLP-1 weight loss drugs).
- Product recall leading to reputational damage.
- Competitive threats lead to market share loss – e.g. pharmaceutical threats to the CPAP market.
- Disappointing growth (company and industry specific).
- Adverse currency movements (AUD, EUR, USD).
- Adverse changes in regulatory & government funding
Subscribe to our newsletter
Disclaimer: This article does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.







